Tissue Selective Estrogen Complex to Prevent Metabolic Dysfunction in Women (TSEC)

Trial Profile

Tissue Selective Estrogen Complex to Prevent Metabolic Dysfunction in Women (TSEC)

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Conjugated estrogens/bazedoxifene (Primary)
  • Indications Menopause; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms RISE
  • Sponsors Pennington Biomedical Research Center
  • Most Recent Events

    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 26 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.
    • 26 Sep 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top